OS Therapies, Inc. (NYSE-A: OSTX) entered into agreements for the commercial manufacture of OST-HER2. The company is ...

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's ...

Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner. Targeting vimentin and/or the long ...

As pet owners, we dread the day our companions show signs of illness, but a vet has explained everything you need to know.

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

IMP761 is a first-in-class agonist LAG-3 antibody designed to restore balance to the immune system by enhancing the "brake” ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune response, and tumor progression, though more research is needed. According ...

How do step-up dosing protocols reduce CRS risk in patients with high-risk disease, and when might you modify this approach? (Dr Allan) How do you incorporate infection prevention strategies, such ...

Background: Osteosarcoma (OS) is one of the most common ... In this study, PPARG knockdown was achieved using small interfering RNA (siRNA) constructs. The cells were seeded in a 6-well plate at a ...